Our research focuses on understanding the role of phosphoinositide signaling in cancer, specifically in human leukemias and pancreatic ductal adenocarcinoma (PDAC). The team aims to uncover genetic alterations and molecular mechanisms that drive cancer development, leading to aggressive behavior and treatment resistance. By investigating these disrupted pathways, they hope to identify potential therapeutic targets for more effective treatments. Additionally, the research seeks to develop innovative therapeutic strategies to tackle the unique challenges posed by these cancers, ultimately improving treatment options and patient outcomes. The goal is to offer insights into the mechanisms of cancer through phosphoinositide signaling, which may lead to novel oncology interventions.